CAC gives clinicians a clear cardiac risk profile with:
Reports summarize these findings in a structured, easy-to-read format, including risk stratification percentiles—helping guide lifestyle andpreventative care discussions.All results are generated directly from a routine chest CT,such as those done for lung cancer screening, without theneed for additional imaging.
CAC™ brings actionable cardiovascular risk data into theworkup of patients with breathlessness, expeditingdiagnosis and guiding referrals.For radiologists, itprovides objective, reproducible quantification, 3Dvisualization, and artery-specific scoring to ensurecomprehensive and efficient interpretation. The result is amore confident, timely distinction between cardiac andpulmonary causes of dyspnea, with higher diagnosticaccuracy and better outcomes for patients.
With CAC, you have a powerful, FDA-cleared tool for fullyautomated detection, visualization,and quantification ofcoronary artery disease—enabling faster, more thorough carefrom a single scan.
Imbio, a fully owned subsidiary of 4DMedical, is the legal manufacturer of CAC
